The European Union (EU) has ratified the contract, which will provide a total of 1.8 billion doses of BioNTech-Pfizer’s vaccine against the new type of coronavirus (Covid-19), 900 million of which are optional.
EU Commission President Ursula von der Leyen announced on her social media account that a new contract has been signed with BioNTech-Pfizer for the purchase of the Covid-19 vaccine.
Pointing out that the vaccination process is progressing well in Europe, Von der Leyen stated that additional doses will be used in the immunization of children and young people in the fight against new variants that have emerged.
Von der Leyen noted that the EU Commission has approved a total of 1.8 billion doses of purchase contracts with BioNTech-Pfizer for 2021-2023, with an option of 900 million doses.
To date, the EU has contracts with BioNTech-Pfizer to receive 2.4 billion doses of vaccines, 400 million with AstraZeneca, 300 million with Sanofi-GSK, 400 million with Johnson & Johnson, 405 million with CureVac, and 460 million with Moderna.
So far, vaccines produced by BioNTech-Pfizer, Moderna, AstraZeneca, and Johnson & Johnson have received EU approval.
With these agreements in mind, the EU administration aims to vaccinate 70 percent of the adult population in the EU, which has a population of 450 million, in the summer.